Technology offer : New Histone Deacetylase (HDAC) inhibitors as treatment for Toxoplasmosis and other parasitic diseases
Deacetylation of histones is required for gene regulation and cell cycle progression, the histone deacetylases, are being pursued as drug targets against parasitic diseases. However current HDAC inhibitors need to be used in high concentration to inhibit parasite growth and additionally most of HDAC inhibitors show little selectivity for intracellular stage of parasites compared to with their selectivity for human cells. Researchers have synthesizedand tested a family of new compound derived from hydroxybenzamide, and observed an HDAC inhibitory activity. In vitro activities of newly synthesized compounds on T.gondii proliferation were compared. Results show that one compound was presenting an inhibiting activity using less than 1ÁM and was the most selective to the intracellular proliferative stage of T.godii. Recently this compound has been successfully tested on the parasite Babesia.
Ref : OT-00024
Area of activity : HEALTH COSMETOLOGY
P: +33 (0)4 91 99 94 27